Dean Winslow | Academic Influence

Dean Winslow's AcademicInfluence.com Rankings

Dean Winslow

Philosophy

#12758

World Rank

#17804

Historical Rank

#2514

USA Rank

Logic

#9701

World Rank

#12337

Historical Rank

#1765

USA Rank

philosophy Degrees

Download Badge

Philosophy

Dean Winslow's Degrees

Bachelors Biology University of California, Berkeley
Doctorate Medicine University of California, San Francisco

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Dean Winslow Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Dean Winslow is an American physician, academic, and retired United States Air Force colonel. He had been nominated by President Donald Trump to become the next Assistant Secretary of Defense for Health Affairs, but he withdrew his nomination in December 2017 after it was put on indefinite hold. He is Professor and former Vice Chair of Medicine at Stanford University. He previously served as Chair of the Department of Medicine and Chief of the Division of AIDS Medicine at the Santa Clara Valley Medical Center. In the Air Force, he deployed twice to Afghanistan and four times to Iraq as a flight surgeon supporting combat operations in Operation Enduring Freedom and Operation Iraqi Freedom.

(See a Problem?)

Dean Winslow's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. (1999) (208)
Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. (1995) (186)
Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. (1996) (163)
Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas. (1996) (151)
Accuracy of the TRUGENE HIV-1 Genotyping Kit (2003) (132)
In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. (1993) (123)
Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines (2018) (123)
HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. (2003) (107)
Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. (1996) (104)
Rhodococcus equi infection in the patient with AIDS: literature review and report of an unusual case. (1991) (93)
Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure. (2020) (86)
Performance Characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System (2003) (85)
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial (2020) (80)
Aphthous ulceration of the gastrointestinal tract in patients with the acquired immunodeficiency syndrome (AIDS). (1990) (64)
Delayed bactericidal activity of beta-lactam antibiotics against Listeria monocytogenes: antagonism of chloramphenicol and rifampin (1983) (61)
Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. (1999) (57)
Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. (1995) (54)
Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. (1996) (54)
Resistance to HIV integrase inhibitors. (2011) (35)
In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor (1993) (32)
Multiple Mutations in the Human Immunodeficiency Virus Protease Gene Are Responsible for Decreased Susceptibility to Protease Inhibitors (1995) (29)
Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors. (1995) (29)
Antibodies reactive with human immunodeficiency virus gag-coded antigens (gag reactive only) are a major cause of enzyme-linked immunosorbent assay reactivity in a blood donor population (1988) (23)
HIV protease inhibitors. (1995) (21)
Efavirenz Plasma Concentrations and Cytochrome 2B6 Polymorphisms (2008) (20)
Efavirenz-Induced Hypersensitivity Reaction Manifesting in Rash and Hepatitis in a Latino Male (2008) (19)
Listeria bacteremia and peritonitis associated with a peritoneovenous shunt: successful treatment with sulfamethoxazole and trimethoprim. (1984) (15)
Cefmetazole treatment of intra-abdominal infection. (1989) (12)
Construction of infectious molecular clones of HIV-1 containing defined mutations in the protease gene. (1994) (11)
Metabolic syndrome in HIV-infected patients. (2007) (9)
Impact of Sepsis Mandates on Sepsis Care: Unintended Consequences. (2020) (8)
Wind, rain, flooding, and fear: coordinating military public health in the aftermath of Hurricane Katrina. (2005) (8)
In vitro susceptibility of clinical isolates of HIV‐1 to XM323, a non‐peptidyl HIV protease inhibitor (1994) (5)
DMP450, a new cyclic urea inhibitor of HIV protease with potent in vitro antiviral activity (1995) (4)
Ventriculoperitoneal shunt infection due to Listeria monocytogenes. (1995) (3)
Treating the Enemy (2007) (3)
Reply to Al-Hasan and Justo. (2018) (2)
Suppurative lymphadenitis caused by hypermucoid-variant Klebsiella in a Polynesian woman: a case report. (2020) (2)
Dideoxynucleoside Resistance Emerges with Prolonged Zidovudine Monotherapy (2003) (2)
Seroconversion on preexposure prophylaxis. (2018) (2)
Blood Donor Population (1)
P63 Design of a randomized trial of combined nucleoside analog antiretroviral therapy in AIDS patients (1993) (1)
HIV integrase inhibitors show potent activity in clinical trials. (2007) (1)
Hepatocyte apoptosis in hepatitis C/HIV co-infection. (2006) (1)
Severe cellulitis due to Aeromonas hydrophilia following immersion injury. (1984) (1)
Acute Kidney Injury Due to Systemic Absorption of Antibiotics Impregnated in a Bone Cement Spacer (2017) (1)
Determination of the optimal cut-offs for predicting the phenotype of nine different HIV drug-resistance algorithms (2002) (1)
Posaconazole for azole-refractory candidiasis in patients with HIV infection. (2007) (1)
Treatment as prevention: some additional thoughts. (2012) (1)
Hepatitis C virus infection and cardiac dysfunction in women. (2021) (0)
Better than nothing: keeping pts on failing regimen has benefits. (2009) (0)
Acquired immune deficiency syndrome in Delaware: experience with opportunistic infections and malignancies in 33 patients. (1986) (0)
New onset kidney impairment in a large pre-exposure prophylaxis demonstration project in New South Wales, Australia. (2021) (0)
Antibiotic choice in the neutropenic patient. (1984) (0)
Efficacy and Safety of Adefovir Dipivoxil With Antiretroviral Therapy (2017) (0)
Pediatric liquid 'single tablet regimens' for HIV-a call to action. (2021) (0)
Complexities of rifamycin use in persons with HIV infection. (2023) (0)
Distinct inflammatory profiles linked to cardiovascular disease risk in HIV infection: implications for the design of preventive and therapeutic interventions. (2023) (0)
Informed consent for transfusion. (1993) (0)
David Katzenstein and James Hakim-In Memoriam. (2021) (0)
Real world reassurance about a misperception. (2009) (0)
Guidelines: opportunistic infections and HIV patients. (2009) (0)
Update on anti-retroviral therapy. (1990) (0)
Replication capacity of HIV-1 in the presence of resistance-associated substitutions in protease. (2009) (0)
Therapeutic trial of growth hormone releasing factor in HIV patients. (2008) (0)
Gross hematuria in a young Iraqi man. (2010) (0)
HIV prevention in serodiscordant pair. (2011) (0)
Addressing the burden of HIV-associated chronic lung disease in West Africa. (2022) (0)
Ciprofloxacin versus ceftazidime in serious infections. (1989) (0)
The Medical Center of Delaware infectious disease clinic. (1989) (0)
Legionnaires' disease. (1979) (0)
Brief report: Ciprofloxacin versus ceftazidime in serious infections (1989) (0)
Book Review Preventing AIDS: The design of effective programs By Ronald O. Valdiserri. 304 pp. New Brunswick, N.J., Rutgers University Press, 1989. $38 (cloth); $15 (paper). (1991) (0)
Infections due to Cryptococcus neoformans. (1985) (0)

This paper list is powered by the following services:

Other Resources About Dean Winslow

en.wikipedia.org

What Schools Are Affiliated With Dean Winslow?

Dean Winslow is affiliated with the following schools:

Image Attributions

Image Source for Dean Winslow